Topical beta-blockers for the treatment of Paronychia

Treatment of Paronychia induced by EGFR inhibitors with topical beta-blockers: a randomized controlled trial - Topical beta-blockers for the treatment of Paronychia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190018

Enrollment

Registered

2019-05-08

Start date

2019-05-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paronychia induced by EGFR inhibitors

Interventions

Randomized

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients over the age of 20 with Grade 2 of paronychia caused by EGFR inhibitors (2) Ambulatory patients can answer survey questions (3) Patients must receive substantial and sufficient explanation of the content of this trial in all its aspects and provide. (4) Patients with self-management of skin and nail care

Exclusion criteria

Exclusion criteria: (1) Patients with bronchial asthma, bronchospasm, chronic obstructive pulmonary disease, and cardiac failure (2) Patients who are deemed unsuitable for inclusion in the study for any other reason based on the assessment by the investigators (3) Patients with allergy for cephem antibiotic

Design outcomes

Primary

Measure	Time frame
Comparison between complete response and partial response of granuloma at week 8	—

Secondary

Measure	Time frame
Safety and adverse effects during the trial period Improvement of periungual erythema and granuloma at week 4 Improvement of periungual erythema and granuloma at week 8	—

Contacts

Public ContactTomoya Watanabe

Yokohama City University Hospital

nabetomo@yokohama-cu.ac.jp+81-45-787-2675

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026